18 December 2014
EMA/PDCO/780247/2014
Paediatric Committee (PDCO)

PDCO monthly report of opinions on paediatric investigation plans and other activities

10 - 12 December 2014

Opinions on paediatric investigation plans

The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:

- Reslizumab, from Teva Pharma GmbH, for the treatment of asthma;
- Roxadustat, from Astellas Pharma Europe B.V., for the treatment of anaemia due to chronic disorders;
- Eluxadoline, from Furiex Pharmaceuticals, Inc, for the treatment of diarrhoea-predominant irritable bowel syndrome;
- Grazoprevir, from Merck Sharp & Dohme (Europe), Inc., for the treatment of chronic hepatitis C;
- Elbasvir, from Merck Sharp & Dohme (Europe), Inc., for the treatment of chronic hepatitis C;
- Grazoprevir / elbasvir, from Merck Sharp & Dohme (Europe), Inc., for the treatment of chronic hepatitis C;
- Finerenone, from Bayer Pharma AG, for the treatment of chronic kidney disease;
- Recombinant human heparan N-sulfatase (rhHNS), from Shire Human Genetic Therapies AB, for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).

A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP aims to generate the necessary quality, safety and efficacy data through studies to support the authorisation of the medicine for use in children of all ages. These data have to be submitted to the European Medicines Agency, or national competent authorities, as part of an application for a marketing authorisation for a new medicine, or for one covered by a patent. In some cases, a PIP may include a waiver of the studies in one or more paediatric subsets, or a deferral.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Adoption of an opinion following re-examination

The PDCO adopted opinions for the following product:

Following the request for re-examination of the negative opinion for a PIP and waiver adopted on 10 October 2014 for Glycopyrronium bromide, from Desitin Arzneimittel GmbH, for the treatment of sialorrhoea, the PDCO maintained its position and adopted a negative opinion.

A re-examination of the opinion can be requested by the applicant within 30 days following receipt of the opinion of the PDCO. The grounds for the re-examination should be based only on the original information and scientific data provided in the application that were previously available to the PDCO and on which the initial opinion was based. This may include new analysis of the same data or minor protocol amendments to a previously proposed study. Significant changes to the previous plan cannot be part of the re-examination process.

Opinions on product-specific waivers

The PDCO adopted positive opinions for product-specific waivers, recommending that the obligation to submit data obtained through clinical studies with children be waived in all subsets of the paediatric population, for the following medicines:

- Everolimus, from Novartis Europharm Ltd, for the treatment of thoracic neuroendocrine tumour;
- Human Papillomavirus type 18 L1 protein / Human Papillomavirus type 16 L1 protein, from GlaxoSmithKline Biologicals SA, for the prevention of infection by human papillomavirus;
- Candesartan (cilexetil) / amlodipine (besilate), from Krka, d.d., Novo mesto, for the treatment of essential hypertension;
- Lutetium [177 Lu] (chloride), from ITG Isotope Technologies Garching GmbH, for the Radiolabelling agent;
- Amlodipine / Perindopril (erbumine), from Actavis Group PTC ehf, for the treatment of hypertension and treatment of stable coronary artery disease.

Waivers can be issued if there is evidence that the medicine concerned is likely to be ineffective or unsafe in the paediatric population, or that the disease or condition targeted occurs only in adult populations, or that the medicine, or the performance of trials, does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Opinions on modifications to an agreed PIP

The PDCO also adopts, every month, opinions on modifications to an agreed PIP, which can be requested by the applicant when the plan is no longer appropriate or when there are difficulties that render the plan unworkable. The PDCO adopted positive opinions, agreeing change(s), for the following products:

- Tiotropium bromide (monohydrate), from Boehringer Ingelheim International GmbH, for the treatment of asthma;
- Denosumab, from Amgen Europe B.V., for the treatment of bone loss associated with sex hormone ablative therapy, prevention of skeletal related events in patients with bone metastases, treatment

of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis) and treatment of giant cell tumour of bone;

- Eltrombopag, from GlaxoSmithKline Trading Services Limited, for the treatment of secondary thrombocytopenia;
- Raltegravir, from Merck Sharp & Dohme (Europe), Inc., for the treatment of human immunodeficiency Virus (HIV-1) infection;
- Rilpivirine (hydrochloride), from Janssen-Cilag International NV, for the treatment of human immunodeficiency virus (HIV-1) infection;
- Conestat alfa, from Pharming Group N.V., for the treatment of hereditary angioedema;
- Secukinumab, from Novartis Europharm Ltd, for the treatment of psoriasis;
- Melatonin, from RAD Neurim Pharmaceuticals EEC Ltd, for the treatment of insomnia;
- Linagliptin, from Boehringer Ingelheim International GmbH, for the treatment of type 2 diabetes mellitus;
- Tofacitinib, from Pfizer Limited, for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis);
- Mirabegron, from Astellas Pharma Europe B.V., for the treatment of idiopathic overactive bladder and treatment of neurogenic detrusor overactivity;
- Eslicarbazepine (acetate), from BIAL - Portela & Ca, SA, for the treatment of epilepsy with partial onset seizures;
- Empagliflozin, from Boehringer Ingelheim International GmbH, for the treatment of type 2 diabetes mellitus;
- Benralizumab, from MedImmune Ltd, for the treatment of asthma;
- Surotomycin, from Cubist (UK) Ltd., for the treatment of clostridia infections;
- Sofosbuvir / ledipasvir, from Gilead Sciences International Ltd, for the treatment of chronic hepatitis C;
- Daclatasvir (dihydrochloride) / asunaprevir / (1aR,12bS)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide hydrochloride (BMS-791325), from Bristol-Myers Squibb International Corporation, for the treatment of chronic hepatitis C.

Opinion on compliance check

The PDCO adopted a positive opinion on (full) compliance check for the following products:

- Tigecycline, from Pfizer Limited, for the treatment of complicated skin and soft tissue infections and treatment of complicated intra-abdominal infections;
- Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted), containing antigen equivalent to Influenza A/California/7/2009 (Produced at Quebec manufacturing site), from GlaxoSmithKline Biologicals S.A., for influenza;

- Split Influenza virus, inactivated, containing antigen: A/California/7/2009 (H1N1)v like strain (X-179A), from GlaxoSmithKline Biologicals S.A., for the prevention of Influenza infection;
- Anakinra, from Swedish Orphan Biovitrum AB (publ), for the treatment of cryopyrin-associated periodic syndromes (CAPS) and treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis).

A compliance check is performed to verify that all the measures agreed in a PIP and reflected in the Agency's decision have been conducted in accordance with the decision, including the agreed timelines. Full compliance with all studies/measured contained in the PIP is one of several prerequisites for obtaining the rewards and incentives provided for in Articles 36 to 38 of the Paediatric Regulation.

Before the submission of a request for a compliance check, applicants are encouraged to consult the Agency's Procedural advice for validation of a new marketing authorisation application or extension/variation application and compliance check with an agreed PIP.

Withdrawals

The PDCO noted that 3 applications were withdrawn during the late stages of the evaluation (30 days or less before completion of the procedure).

Other matters

The PDCO welcomed Ninna Gullberg in her new role as member and Anna-Karin Hamberg in her new role as alternate, nominated to represent Sweden.

The PDCO thanked Viveca Odlind for her work as she resigned from the Committee.

The PDCO welcomed Ann Marie Kaukonen in her new role as member and Maija Pihlajamaki in her new role as alternate, nominated to represent Finland.

The PDCO thanked Pirjo Laitinen-Parkkonen for her work at the end of her mandate as member.

The next meeting of the PDCO will be held on 14-16 January 2015.

– END –

Notes:

1. As of 26 January 2009, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product, or those that submit an application for an extension of indication, a new route of administration, or a new pharmaceutical form of a medicinal product already authorised in the European Union, have to provide either the results of studies in children conducted in accordance with an approved PIP, or an Agency's decision on a waiver or on a deferral.

2. PDCO opinions on PIPs and waivers are transformed into Agency's decisions within the timeframe laid down by the Paediatric Regulation (Regulation (EC) No 1901/2006, as amended). The decisions can be found on the Agency's website at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d129

3. More information about the PDCO and the Paediatric Regulation is available in the Regulatory section of the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000023.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240cd

4. This meeting report, together with other information on the work of the Agency's, can be found on the Agency's website: http://www.ema.europa.eu

Enquiries to: AskEMA
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ask_ema_landing_page.jsp&mid=)